The benefits and pitfalls of trained immunity in listeria monocytogenes-based cancer vaccination: how host innate-cell reprogramming may amplify, distort, or constrain the therapeutic potential of live bacterial vectors
Abstract
Live recombinant Listeria monocytogenes (Lm) vaccines are usually framed as intracellular antigen-delivery platforms endowed with intrinsic adjuvant activity. Here we argue that this view may be incomplete. Because Lm vaccines strongly engage innate immune cells, their efficacy might depend on both immediate inflammatory signaling and a separately established or acquired trained state. Importantly, direct evidence that recombinant Lm induces bona fide trained immunity - defined by durable functional changes supported by epigenetic and metabolic reprogramming beyond the initial inflammatory phase - is currently limited. We consider two distinct questions: whether pre-existing trained immunity changes the efficacy of subsequent Lm vaccination, and whether Lm vaccination itself induces a lasting trained innate program in addition to antigen-specific CD8 T-cell immunity. Pre-existing training could alter vector clearance, antigen presentation, and initial T-cell priming, whereas hypothetical Lm-induced training could affect later tumor-microenvironment function, memory recall, and long-term tumor control without accounting for the initial CD8 T-cell response. Either scenario might enhance or constrain efficacy, and the two require different experimental examinations. We propose trained innate reprogramming as a testable mechanistic variable, rather than an established property of Lm vaccines, with implications for vaccine design, repeated dosing, safety, and interpretation of antitumor vaccines.
Related
- Epigenetic reprogramming by BCG (Bacillus Calmette-Guérin) vaccination: A novel strategy to reverse immunodeficiency in chronic kidney disease.
- Editorial: The differentiation and reprogramming of tumor-associated myeloid cells and therapeutic strategies for cancer immunotherapy
- CD8+ stem cell-like memory T cells: Unveiling the potential for next-generation vaccination strategies
- Therapeutic HPV16 E7 vaccination with CD137 agonism induces tumor regression and durable immunity in mice
- Immune cell metabolic reprogramming in pancreatic cancer: roles in tumor progression and therapeutic strategies
BibTeX
@article{amarantemendes2026benefits,
title = {{The benefits and pitfalls of trained immunity in listeria monocytogenes-based cancer vaccination: how host innate-cell reprogramming may amplify, distort, or constrain the therapeutic potential of live bacterial vectors}},
author = {Gustavo P. Amarante-Mendes and Maria Alice Leão de Freitas and Mariana Figueira Theodoro and Barbara Heloisa de Lima and Abolaji Samson Olagunju and Sergio Costa Oliveira and Karina R. Bortoluci},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1930081},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1930081},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The benefits and pitfalls of trained immunity in listeria monocytogenes-based cancer vaccination: how host innate-cell reprogramming may amplify, distort, or constrain the therapeutic potential of live bacterial vectors
AU - Gustavo P. Amarante-Mendes
AU - Maria Alice Leão de Freitas
AU - Mariana Figueira Theodoro
AU - Barbara Heloisa de Lima
AU - Abolaji Samson Olagunju
AU - Sergio Costa Oliveira
AU - Karina R. Bortoluci
PY - 2026
DA - 2026/11/06
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1930081
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1930081
AB - Live recombinant Listeria monocytogenes (Lm) vaccines are usually framed as intracellular antigen-delivery platforms endowed with intrinsic adjuvant activity. Here we argue that this view may be incomplete. Because Lm vaccines strongly engage innate immune cells, their efficacy might depend on both immediate inflammatory signaling and a separately established or acquired trained state. Importantly, direct evidence that recombinant Lm induces bona fide trained immunity - defined by durable functional changes supported by epigenetic and metabolic reprogramming beyond the initial inflammatory phase - is currently limited. We consider two distinct questions: whether pre-existing trained immunity changes the efficacy of subsequent Lm vaccination, and whether Lm vaccination itself induces a lasting trained innate program in addition to antigen-specific CD8 T-cell immunity. Pre-existing training could alter vector clearance, antigen presentation, and initial T-cell priming, whereas hypothetical Lm-induced training could affect later tumor-microenvironment function, memory recall, and long-term tumor control without accounting for the initial CD8 T-cell response. Either scenario might enhance or constrain efficacy, and the two require different experimental examinations. We propose trained innate reprogramming as a testable mechanistic variable, rather than an established property of Lm vaccines, with implications for vaccine design, repeated dosing, safety, and interpretation of antitumor vaccines.
SN - 1664-3224
ER -